400-920-2911 sales@csnpharm.cn
CAS No.: 1227637-23-1
Synonyms: BC2059;Tegavivint
beta-Catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma.
规格 | 价格 | 促销价格 | 库存 | 数量 |
---|
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT03459469 | Desmoid Tumor | Phase 1 | Recruiting | November 1, 2019 | United States, California ... more >> Jonsson Comprehensive Cancer Center Not yet recruiting Los Angeles, California, United States, 90095 Principal Investigator: Noah Federman, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Julia DiGiovanni Principal Investigator: Edwin Choy, MD United States, New York Memorial Sloan Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Principal Investigator: Mrinal Gounder, MD United States, Ohio The Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43202 Principal Investigator: David Liebner, MD United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 770030 Principal Investigator: Ravi Vinod, MD United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore Principal Investigator: Lee Cranmer, MD Canada, Ontario Princess Margaret Cancer Center Recruiting Toronto, Ontario, Canada Contact: Maryam Masood Principal Investigator: Albiruni Razak Collapse << |
实验方案
技术信息
CAS号 | 1227637-23-1 | 储存条件 |
|
|||||
分子式 | C28H36N4O6S2 | 运输 | 蓝冰 | |||||
分子量 | 588.74 | 别名 | BC2059;Tegavivint | |||||
溶解度 |
|
动物实验配方 |